[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"airway-clearance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:airway-clearance":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,77,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100625308","mechanical-insufflation-exsufflation-in-critically-ill-patients-100625308",false,"NCT07420946","Mechanical Insufflation-Exsufflation in Critically Ill Patients","Mechanical Insufflation-Exsufflation in Critically Ill Patients: An International DELphi Consensus (DELMI-E)","DELMI-E","Inclusion Criteria:\n\n* Healthcare professionals with documented clinical experience in critical care medicine, pulmonology, anesthesiology, respiratory therapy, or physiotherapy with involvement in airway clearance strategies.\n* Demonstrated experience or recognized expertise in the clinical use of MI-E, either in critically ill patients or in patients with complex respiratory conditions.\n* A minimum of 5 years of clinical experience in their respective field, or a proven academic or clinical contribution related to MI-E.\n* Willingness to participate in multiple Delphi rounds and to provide informed consent.\n* Ability to complete the questionnaires in English.\n\nExclusion Criteria:\n\n* Lack of direct clinical or academic experience related to MI-E or airway clearance techniques.\n* Inability or unwillingness to provide informed consent.\n* Failure to complete the first Delphi round after formal invitation and consent.\n* Withdrawal of consent at any stage of the Delphi process.","ALL",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Mechanical insufflation-exsufflation (MI-E) is an established airway clearance technique for patients with chronic conditions like neuromuscular diseases. However, its use in critically ill ICU patients remains inconsistent and lacks standardized guidelines. Despite growing research, current practices vary widely in patient selection, treatment protocols, and safety management, with limited high-quality evidence to support clear recommendations. To address this gap, an international, multidisciplinary Delphi consensus study is needed to establish expert-based best practices and feasible guidelines for the safe and effective implementation of MI-E in the intensive care setting.",[24,25,26,27,28,29,30,31],"Airway Clearance","Mechanical Insufflation-exsufflation","Mechanical Insufflation-exsufflation Session ( With Cough Assist)","Delphi Study","Consensus","Critical Illness","Critical Care","Critical Care, Intensive Care",[33,34,35,28,36,37,38],"mechanical insufflation-exsufflation","Airway clearance","Delphi study","Cough assist","MI-E","critical care","RECRUITING","2026-06-15",{"date":42,"type":43},"2026-06-17","ACTUAL",{"date":45,"type":43},"2026-06-10",{"date":47,"type":20},"2026-12-01",{"name":49,"class":50},"Medipol University","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100638894","the-effectiveness-of-different-nebulized-solutions-on-airway-clearance-function-in-patients-with-pneumonia-100638894","NCT07586345","The Effectiveness of Different Nebulized Solutions on Airway Clearance Function in Patients With Pneumonia","Inclusion Criteria:\n\n1. Diagnosed with pneumonia, defined by ICD-10 codes, including:\n\n   J18: Pneumonia, unspecified organism J180: Bronchopneumonia, unspecified organism J181: Lobar pneumonia, unspecified organism J182: Hypostatic pneumonia, unspecified organism J188: Other pneumonia, unspecified organism J189: Pneumonia, unspecified organism\n2. Aged 18-100 years\n3. Clinical respiratory score \\> 3\n4. Patients unable to expectorate sputum spontaneously and requiring assisted suctioning\n\nExclusion Criteria:\n\n1. Diagnosis of influenza-associated pneumonia, defined by ICD-10 codes, including:\n\n   J09X1: Influenza due to identified novel influenza A virus with pneumonia J1001: Influenza due to other identified influenza virus with the same identified influenza viral pneumonia J100: Influenza due to other identified influenza virus with pneumonia\n2. Diagnosis of COVID-19 infection, defined by ICD-10 code:\n\n   U07.1: COVID-19, virus identified\n3. History of chronic obstructive pulmonary disease (COPD) (ICD-10 code: J44)\n4. History of lung cancer or metastatic cancer involving the lungs\n5. Current use of bronchodilators\n6. Patients requiring oral suctioning only\n7. Oxygen therapy with a flow rate \\> 10 L\u002Fmin\n8. Clinical respiratory score \\> 8 (Table 2)","18 Years","100 Years",{"count":60,"type":20},80,"INTERVENTIONAL",[63],"NA","Pneumonia is a significant global and national health issue, particularly posing a notable threat to elderly population. Accumulation of sputum in pneumonia patients often results in impaired airway clearance, negatively impacting disease management and recovery. Clinically, nebulization therapy is widely employed to facilitate sputum clearance; however, evidence regarding the comparative effectiveness of different nebulized solution concentrations remains limited and inconsistent. Therefore, this study aims to evaluate and compare the clinical effects of nebulized solutions with various osmotic concentrations (3% hypertonic saline, 0.9% normal saline, 0.45% hypotonic saline, and distilled water) on airway clearance in patients with pneumonia. A randomized, double-blind controlled trial design will be used, recruiting 80 patients with pneumonia from a regional teaching hospital in northern Taiwan. Participants will be randomly assigned into four groups, receiving nebulized therapy four times daily over a period of seven days. This study outcome including the length of hospital stay, venous blood gas analysis, routine sputum examination, and arterial oxygen content. The findings of this the study are anticipated to provide evidence-based recommendations for the clinical application of nebulized solutions with different concentrations, aiming to enhance airway clearance efficiency, improve clinical care outcomes for pneumonia patients, and serve as a practical reference for healthcare professionals.",[66,24],"Pneumonia","NOT_YET_RECRUITING","2026-05-12",{"date":70,"type":43},"2026-05-14",{"date":72,"type":20},"2026-05-01",{"date":74,"type":20},"2027-12-31",{"name":76,"class":50},"Chen, Yao-Hsiang",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":86,"conditions":87,"keywords":94,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100620826","a-study-of-the-efficacy-and-safety-of-bronchoscopic-airway-clearance-and-amphotericin-b-spraying-in-patients-with-abpa-100620826","NCT07362667","A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).\n2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a \\> 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.\n3. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);\n2. Patients with absolute or relative contraindications to electronic bronchoscopy;\n3. Known history of allergy to amphotericin B or any of its excipients;\n4. Patients with bronchiectasis caused by human immunodeficiency virus infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;\n5. Combined with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n6. Patients with previous or current smoking history;\n7. Pregnant or lactating women;\n8. Currently participating in other interventional clinical research;\n9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":85,"type":20},44,"To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis",[88,89,90,24,91,92,93],"ABPA","Allergic Bronchopulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis (ABPA)","Mucus Plug","Amphotericin B","Bronchoscope",[89,88,92,95,24,96],"bronchoscope","mucus plug","2026-01-15",{"date":99,"type":43},"2026-01-23",{"date":101,"type":43},"2026-01-10",{"date":103,"type":20},"2028-12-31",{"name":105,"class":50},"Qianfoshan Hospital",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":115,"targetDuration":4,"studyType":61,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":106},"100577981","lung-recruitment-during-chest-physiotherapy-in-mechanically-ventilated-patients-100577981","NCT06805357","Lung Recruitment During Chest Physiotherapy in Mechanically Ventilated Patients","Evaluation of Lung Recruitment During Chest Physiotherapy in Mechanically Ventilated Patients","RECRUTKI","Inclusion Criteria:\n\n* Patient under assisted ventilation (in V-ACV or PSV) triggering all ventilator cycles\n* Patient deemed \" secretive \": requiring ≥ 2 tracheal aspirations every 3 hours\n* Patient (or relative) who has given consent to participate in the research\n* Patient covered by social security\n\nExclusion Criteria:\n\n* Age under 18 years\n* Legal guardian required\n* Recent cardiac and\u002For thoracic and\u002For abdominal surgery (\\\u003C 3 months)\n* Rib fracture(s)\n* Pneumothorax and\u002For presence of a chest drain\n* Recent neurosurgery (\\\u003C 3 months) and\u002For proven or suspected increased intracranial pressure (ICP)\n* Hemodynamic instability defined as: noradrenaline ≥ 1mg\u002Fh, adrenaline ≥ 0.5 mg\u002Fh, dobutamine ≥ 5γ\u002Fkg\u002Fmin.\n* Respiratory instability defined as: PEEP \\> 10 cmH2O and\u002For PaO2\u002FFiO2 \\\u003C 150 mm Hg\n* Pregnancy\n* Hemoptysis\n* Sever skin lesions (e.g., burns, Lyell's syndrome)\n* Patient under foreign health insurance",{"count":116,"type":20},40,[63],"In intensive care, respiratory physiotherapy is an integral part of the daily care of patients under invasive mechanical ventilation. Its goals are to improve the clearance of bronchial secretions to allow for the resolution of atelectasis and alveolar recruitment, thereby enhancing respiratory mechanics and gas exchange. The most widespread technique in France is external expiratory compression of the chest.\n\nThe effectiveness of this technique depends on the selection of patients (it seems to be more effective in patients with higher secretion levels) and on the practical implementation of the technique (favoring brief and vigorous compressions at the beginning of expiration). However, the effect of the artificial ventilator settings, particularly the ventilatory mode used during the respiratory physiotherapy session, has never been evaluated. The two most commonly used ventilatory modes worldwide are Volume Assist Control Ventilation (V-ACV) and pressure support ventilation (PSV). In this unit, respiratory physiotherapy under artificial ventilation is performed daily on patients with artificial ventilation with abundant secretions, regardless of the ventilatory mode.",[120,121,122,24],"Intensive Care","Invasive Mechanical Ventilation","Chest Physiotherapy",[124,125,126,127,128,129],"ICU","Lung recruitment","Respiratory physiotherapy","Rib Cage Compressions (RCC)","mechanical ventilation","intensive care","2026-01-14",{"date":97,"type":43},{"date":133,"type":43},"2024-07-23",{"date":135,"type":20},"2027-06-23",{"name":137,"class":50},"Assistance Publique - Hôpitaux de Paris"]